hotspot -WSS

hotspot

author：hotspot 2025-10-01 17:20:06 - browse：2889

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： A virus, fished out of a lake, may have saved a man’s life

leisure time

WSS

House GOP plan to stem drug shortages differs from Democrats’

Bill would stop addiction treatment from triggering child abuse inquiry

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

Phenylephrine and the overlooked value of the placebo effect

3 questions for the future of Biden's cancer moonshot

American TikTok star stuck in Dubai for months following rental car altercation

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Medical leaders decry Supreme Court decision on affirmative action

Snowpack in the West is melting rapidly. Where will all that extra water go?

Medicare details structure of new drug price negotiation program

Sana to lay off nearly a third of staff, de

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Liquid biopsy for lung cancer is launched by Delfi

Affirmative action in medical school literally saved lives

When women are denied an abortion, their children fare worse than peers

hotspot

3 questions for the future of Biden's cancer moonshot

9 mass shootings over the weekend rock US cities, leaving 5 dead, 56 injured

Why Charlie Gard's case is so disturbing to Americans

Senate panel eyes new effort on drug shortages

Trump team launching legal defense fund to help pay legal bills

Poland's lawmakers approve a divisive law on Russian influence

leisure time

knowledge

hotspot

leisure time